Found 22 results
[ Author(Asc)] Keyword Title Type Year
Filters: First Letter Of Last Name is S  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
R. P. Symonds, Davidson, S. E., Chan, S., Reed, N. Simon, McMahon, T., Rai, D., Harden, S., Paul, J., Group, S. Gynaecolog, and Centre, B. West of Sc, SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer, Gynecol Oncol, vol. 123, pp. 105-9, 2011.
N. Susumu, Sagae, S., Udagawa, Y., Niwa, K., Kuramoto, H., Satoh, S., Kudo, R., and Group, J. Gynecologi, Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study, Gynecol Oncol, vol. 108, pp. 226-33, 2008.
T. Sugiyama, Kumagai, S., and Hatayama, S., [Treatments of epithelial ovarian cancer by histologic subtype], Gan To Kagaku Ryoho, vol. 36, pp. 187-92, 2009.
T. Sugiyama, Fujiwara, K., Ohashi, Y., Yokota, H., Hatae, M., Ohno, T., Nagai, Y., Mitsuhashi, N., Ochiai, K., and Noda, K., Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study., Ann Oncol, vol. 25, no. 5, pp. 1011-7, 2014.
G. C. E. Stuart, Future opportunities of the Gynecological Cancer Intergroup., Int J Gynecol Cancer, vol. 18 Suppl 1, pp. 71-3, 2008.
G. C. E. Stuart, Åvall-Lundqvist, E., du Bois, A., Bookman, M. A., Bowtell, D. D. L., Brady, M. F., Casado, A., Cervantes, A., Eisenhauer, E., Friedlander, M. Leonard, Fujiwara, K., Grenman, S., Guastalla, J. P., Harper, P., Högberg, T., Kaye, S. B., Kitchener, H. C., Kristensen, G. B., Mannel, R., Meier, W., Miller, B., Oza, A. M., Ozols, R., Parmar, M. K. B., Pfisterer, J., Poveda, A. M., Provencher, D. M., Pujade-Lauraine, E., Quinn, M., Randall, M., Rochon, J., Rustin, G. J. S., Sagae, S., Stehman, F. B., Trimble, E. L., Thigpen, T., Vasey, P. A., Vergote, I. B., Verheijen, R. H. M., Vermorken, J. B., and Wagner, U., 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration., Ann Oncol, vol. 16 Suppl 8, pp. viii36-viii38, 2005.
G. C. E. Stuart, Kitchener, H. C., Vermorken, J. B., Quinn, M., Small, W., Pujade-Lauraine, E., Chou, H., Wong, M., and Bacon, M., The Impact of an International Network (Gynecologic Cancer InterGroup) for Clinical Research on Global Capacity for Gynecologic Cancer Clinical Trials., Int J Gynecol Cancer, 2017.
G. C. E. Stuart, Future opportunities of the Gynecological Cancer Intergroup, Int J Gynecol Cancer, vol. 18 Suppl 1, pp. 71-3, 2008.
G. C. E. Stuart, Kitchener, H. C., Bacon, M., du Bois, A., Friedlander, M. Leonard, Ledermann, J. A., Marth, C., Thigpen, T., and Trimble, E. L., 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference., Int J Gynecol Cancer, vol. 21, no. 4, pp. 750-5, 2011.
M. R. Stockler, Hilpert, F., Friedlander, M. Leonard, King, M. Trudy, Wenzel, L. B., Lee, C. Khoon, Joly, F., de Gregorio, N., Arranz, J. Angel, Mirza, M. Raza, Sorio, R., Freudensprung, U., Sneller, V., Hales, G., and Pujade-Lauraine, E., Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer., J Clin Oncol, vol. 32, no. 13, p. 1316, 2014.
K. D. Steffensen, Waldstrom, M., Pallisgard, N., Lund, B., Bergfeldt, K., Wihl, J., Keldsen, N., Marth, C., Vergote, I. B., and Jakobsen, A., Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study, Int J Gynecol Cancer, vol. 23, pp. 73-80, 2013.
D. Stark, Nankivell, M., Pujade-Lauraine, E., Kristensen, G. B., Elit, L., Stockler, M., Hilpert, F., Cervantes, A., Brown, J., Lanceley, A., Velikova, G., Sabate, E., Pfisterer, J., Carey, M. S., Beale, P., Qian, W., Swart, A. Marie, Oza, A. M., and Perren, T. J., Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial., Lancet Oncol, vol. 14, no. 3, p. 243, 2013.
M. P. Smerdel, Steffensen, K. D., Waldstrom, M., Brandslund, I., and Jakobsen, A., The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab, Gynecol Oncol, vol. 118, pp. 167-71, 2010.
W. Small, Mell, L. K., Anderson, P., Creutzberg, C., Santos, J. De Los, Gaffney, D. K., Jhingran, A., Portelance, L., Schefter, T., Iyer, R., Varia, M., Winter, K., and Mundt, A. J., Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer., Int J Radiat Oncol Biol Phys, vol. 71, no. 2, pp. 428-34, 2008.
W. Small, du Bois, A., Bhatnagar, S., Reed, N. Simon, Pignata, S., Potter, R., Randall, M., Mirza, M., Trimble, E. L., Gaffney, D. K., and InterGroup, G. Cancer, Practice patterns of radiotherapy in endometrial cancer among member groups of the Gynecologic Cancer Intergroup, Int J Gynecol Cancer, vol. 19, pp. 395-9, 2009.
W. Small, Bacon, M., Bajaj, A., Chuang, L. T., Fisher, B. J., Harkenrider, M. M., Jhingran, A., Kitchener, H. C., Mileshkin, L. R., Viswanathan, A., and Gaffney, D. K., Cervical cancer: A global health crisis., Cancer, vol. 123, no. 13, pp. 2404-2412, 2017.
M. Signorelli, Lissoni, A., Cormio, G., Katsaros, D., Pellegrino, A., Selvaggi, L., Ghezzi, F., Scambia, G., Zola, P., Grassi, R., Milani, R., Giannice, R., Caspani, G., Mangioni, C., Floriani, I., Rulli, E., and Fossati, R., Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study, Ann Surg Oncol, vol. 16, pp. 3431-41, 2009.
D. Shaw, Clamp, A. R., and Jayson, G. C., Angiogenesis as a target for the treatment of ovarian cancer, Curr Opin Oncol, vol. 25, pp. 558-65, 2013.
T. Satoh, Takei, Y., Treilleux, I., Devouassoux-Shisheboran, M., Ledermann, J. A., Viswanathan, A., Mahner, S., Provencher, D. M., Mileshkin, L. R., Åvall-Lundqvist, E., Pautier, P., Reed, N. Simon, and Fujiwara, K., Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S102-8, 2014.
S. Sagae, Monk, B. J., Pujade-Lauraine, E., Gaffney, D. K., Narayan, K., Ryu, S. Young, McCormack, M., Plante, M., Casado, A., Reuss, A., Chávez-Blanco, A., Kitchener, H. C., Nam, B. - H., Jhingran, A., Temkin, S., Mileshkin, L. R., Berns, E. M. J. J., Scholl, S., Doll, C., Abu-Rustum, N. R., Lecuru, F., and Small, W., Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future., Int J Gynecol Cancer, vol. 26, no. 1, p. 207, 2016.
S. Sagae, Aoki, D., Susumu, N., Okamoto, A., Aotani, E., Takeuchi, M., and Mandai, M., [Current movement in global clinical trials–discussion at Gynecologic Cancer Intergroup (GCIG)], Nihon Rinsho, vol. 70 Suppl 4, pp. 59-66, 2012.
S. Sagae, Susumu, N., Viswanathan, A., Aoki, D., Backes, F. J., Provencher, D. M., Vaughan, M., Creutzberg, C. L., Kurzeder, C., Kristensen, G. B., Lee, C., Kurtz, J. - E., Glasspool, R. M., and Small, W., Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S83-9, 2014.